ORIGINAL RESEARCH article

Front. Immunol.

Sec. Primary Immunodeficiencies

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1596963

The effects of postponing BCG vaccination on the risk of BCGrelated complications among patients with severe combined immunodeficiency disease in Saudi Arabia

Provisionally accepted
Amal  AldhaheriAmal Aldhaheri1Ohoud  AlyabesOhoud Alyabes1,2*Suliman  AljumaahSuliman Aljumaah1,2Raghad  AlhuthilRaghad Alhuthil1Raghad  AlonaziRaghad Alonazi2Shefa  AlamoudiShefa Alamoudi2Mohammed  AlsuhaibaniMohammed Alsuhaibani1,2Salem  AlghamdiSalem Alghamdi1,2Esam  A AlbanyanEsam A Albanyan1,2Sami  Al-HajjarSami Al-Hajjar1,2Reem  Walid MohammedReem Walid Mohammed1Rand  K. ArnaoutRand K. Arnaout1Sultan  AlbuhairiSultan Albuhairi1Nora  AlRumayyanNora AlRumayyan1Bandar  Al-SaudBandar Al-Saud1Hamoud  Al-MousaHamoud Al-Mousa1,2*
  • 1King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
  • 2Alfaisal University, Riyadh, Saudi Arabia

The final, formatted version of the article will be published soon.

The Bacillus Calmette-Guérin (BCG) vaccine is widely used to prevent tuberculosis but is associated with significant complications in patients with severe combined immunodeficiency (SCID). Considering the high incidence of SCID in Saudi Arabia, the Ministry of Health revised its national vaccination schedule in 2019, postponing BCG administration from birth to 6 months of age, aiming to enable time for the diagnosis of primary immunodeficiency diseases before vaccination. This study evaluated the consequences of this policy change on the incidence of BCG-related complications in SCID patients.This retrospective study included 178 SCID patients diagnosed at King Faisal Specialist Hospital and Research Center, Riyadh, between 2015 and 2023. Patients were divided into two cohorts: Era 1 (2015-2019), when BCG vaccination was administered at birth, and Era 2 (2019-2023), when BCG vaccination was administered at 6 months of age. Data on demographics, clinical presentations, BCG-related complications, genetic testing, treatment, and outcomes were analyzed.A total of 49 SCID patients developed BCGitis, of which 65.3% experienced disseminated disease. The incidence of BCG-related complications dropped significantly after the policy change, from 46.1% in Era 1 to 2.6% in Era 2. Patients required stem cell transplantation and a median of 17.6 months of anti-mycobacterial therapy. The crude mortality rate was high (36.7%; 18/49), with 66.7% (12/18) of these fatalities linked to disseminated BCGitis.Postponing BCG vaccination to 6 months of age significantly decreases the incidence of BCGrelated complications in SCID patients and highlights the importance of tailoring vaccination schedules for high-risk populations. Early newborn screening and timely diagnosis of immunodeficiencies are essential to further minimize complications. The revised vaccination policy of Saudi Arabia provides a model for optimizing immunization strategies in regions with a high prevalence of inborn errors of immunity.

Keywords: Bacillus calmette guerin, severe combined immunodeficiency disease, Vaccination, Saudi Arabia, Tuberculosis

Received: 20 Mar 2025; Accepted: 18 Apr 2025.

Copyright: © 2025 Aldhaheri, Alyabes, Aljumaah, Alhuthil, Alonazi, Alamoudi, Alsuhaibani, Alghamdi, Albanyan, Al-Hajjar, Mohammed, Arnaout, Albuhairi, AlRumayyan, Al-Saud and Al-Mousa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Ohoud Alyabes, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Hamoud Al-Mousa, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.